Henry Ford Hospital Medical Journal


Based on experience with 30 men having clinical stage A and B adenocarcinoma of the prostate, the authors conclude that elevation of bone marrow acid phosphatase (BMAP) is a sensitive indicator of the disease state. BMAP revealed periprostatic or nodal Involvement when osseous metastases seemed absent. BMAP is considered essential in the evaluation of all patients with prostatic carcinoma. Patients who have false negative BMAP (and are not candidates for radical prostatectomy), should undergo lymphangiography and bone scan before radiation therapy or hormonal treatment is planned.



To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.